Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma

[1] Kaka N(2019)Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: a systematic review and meta-analysis Cancers 11 1723-307

[2] Hafazalla K(2020)Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis J Neurooncol 147 297-996

[3] Samawi H(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-122

[4] Simpkin A(2014)Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma Neuro-Oncol 16 113-198

[5] Perry J(2001)A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg 95 190-1963

[6] Sahgal A(2017)Lomustine and bevacizumab in progressive glioblastoma N Engl J Med 377 1954-722

[7] Marenco-Hillembrand L(2014)Bevacizumab plus radiotherapy temozolomide for newly diagnosed glioblastoma N Engl J Med 370 709-708

[8] Wijesekera O(2014)A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 699-2316

[9] Suarez-Meade P(2017)Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial JAMA 318 2306-1018

[10] Mampre D(1979)Quality and duration of survival in glioblastoma multiforme: combined surgical, radiation, and lomustine therapy JAMA 241 1016-343

[1] Kaka N(2019)Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: a systematic review and meta-analysis Cancers 11 1723-307

[2] Hafazalla K(2020)Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis J Neurooncol 147 297-996

[3] Samawi H(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-122

[4] Simpkin A(2014)Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma Neuro-Oncol 16 113-198

[5] Perry J(2001)A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg 95 190-1963

[6] Sahgal A(2017)Lomustine and bevacizumab in progressive glioblastoma N Engl J Med 377 1954-722

[7] Marenco-Hillembrand L(2014)Bevacizumab plus radiotherapy temozolomide for newly diagnosed glioblastoma N Engl J Med 370 709-708

[8] Wijesekera O(2014)A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 699-2316

[9] Suarez-Meade P(2017)Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial JAMA 318 2306-1018

[10] Mampre D(1979)Quality and duration of survival in glioblastoma multiforme: combined surgical, radiation, and lomustine therapy JAMA 241 1016-343